MarketCap
Madrigal Pharmaceuticals MDGL
$ 507.56
0.04%
Facebook
X
Telegram
Madrigal Pharmaceuticals Operating Expenses | MDGL
Annual Operating Expenses Madrigal Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.26 B | 678 M | 380 M | 85.3 M | 242 M | 207 M | 95 M | 40.7 M | 32.1 M | 25.2 M | 67.6 M | 84 M | 87.6 M | 61.1 M | 53 M | 51.7 M | 64.9 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.26 B | 25.2 M | 207 M |
Quarterly Operating Expenses Madrigal Pharmaceuticals
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 421 M | 404 M | 401 M | 260 M | 217 M | - | 178 M | 177 M | 152 M | - | 98.5 M | 86.4 M | 78.3 M | - | 80.4 M | 70.3 M | 57.6 M | 64.6 M | 63.2 M | 61.7 M | 53 M | 59.6 M | 58.8 M | 50.3 M | 38 M | 30 M | 24.2 M | 22.7 M | 18.1 M | 14.5 M | 11.3 M | 7.83 M | 7.07 M | 8.91 M | 8.64 M | 8.44 M | 6.08 M | - | 14.1 M | 2.64 M | 738 K | 10.4 M | 880 K | 19.5 M | 20.3 M | 19.9 M | 19.4 M | 21.7 M | 22.9 M | 23.4 M | 21.8 M | 22.1 M | 20.3 M | 17.7 M | 14.5 M | 14.1 M | 14.7 M | 13.7 M | 13.9 M | 13.4 M | 12.1 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 421 M | 738 K | 64.1 M |
Operating Expenses of other stocks in the Biotechnology industry
| Issuer | Operating Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Celsion Corporation
CLSN
|
14.7 M | - | -6.63 % | $ 13.9 M |  USA |
 |
FSD Pharma
HUGE
|
15.3 M | - | 5743.5 % | $ 69.7 M |  Canada |
 |
Qilian International Holding Group Limited
QLI
|
2.16 M | - | -6.08 % | $ 184 M |  China |
 |
Happiness Biotech Group Limited
HAPP
|
6.79 M | - | 1.35 % | $ 17.8 M | China |
 |
Synthetic Biologics
SYN
|
24.1 M | - | 1.32 % | $ 16.2 M | USA |
 |
Dynavax Technologies Corporation
DVAX
|
137 M | - | - | $ 2.02 B | USA |
 |
BioXcel Therapeutics
BTAI
|
107 M | $ 1.19 | 5.31 % | $ 14.5 M | USA |
 |
Burford Capital Limited
BUR
|
181 M | $ 4.37 | 0.23 % | $ 958 M |  Britain |
 |
I-Mab
IMAB
|
1.49 B | - | - | $ 866 M | China |
 |
BeyondSpring
BYSI
|
40.3 M | $ 0.84 | 34.27 % | $ 34.5 M | USA |
 |
AgeX Therapeutics
AGE
|
24.2 M | - | -10.17 % | $ 12.2 K | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
2.66 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
78.3 M | - | 2.54 % | $ 160 B |  France |
 |
Cerus Corporation
CERS
|
149 M | $ 2.98 | 4.93 % | $ 568 M | USA |
 |
Compugen Ltd.
CGEN
|
32.2 M | $ 2.41 | 4.17 % | $ 225 M |  Israel |
 |
CureVac N.V.
CVAC
|
88.9 M | - | - | $ 867 M |  Germany |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.22 M | - | -1.52 % | $ 24.7 M | USA |
 |
Athira Pharma
ATHA
|
18.7 M | - | - | $ 269 M | USA |
 |
BiondVax Pharmaceuticals Ltd.
BVXV
|
78.4 M | - | 0.74 % | $ 768 M | Israel |
 |
Abcam plc
ABCM
|
170 M | - | - | $ 4.9 B | Britain |
 |
Завод ДИОД
DIOD
|
249 M | - | - | - |  Russia |
|
Galera Therapeutics
GRTX
|
70.6 M | - | -32.59 % | $ 7.61 M | USA |
 |
Midatech Pharma plc
MTP
|
4.78 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Hepion Pharmaceuticals
HEPA
|
4.16 M | - | -18.79 % | $ 39.3 K | USA |
 |
ARCA biopharma
ABIO
|
122 M | - | 1052.0 % | $ 415 M | USA |
 |
MorphoSys AG
MOR
|
432 M | - | 2.43 % | $ 254 M | Germany |
|
Champions Oncology
CSBR
|
12.5 M | $ 5.1 | 2.63 % | $ 70.5 M | USA |
 |
Affimed N.V.
AFMD
|
54 M | - | -34.95 % | $ 21.5 M | Germany |
 |
AnPac Bio-Medical Science Co., Ltd.
ANPC
|
106 M | - | -1.58 % | $ 28.1 M | China |
 |
Celyad Oncology SA
CYAD
|
26.2 M | - | - | $ 12.5 M |  Belgium |
 |
Adial Pharmaceuticals
ADIL
|
7.8 M | $ 3.98 | 1.86 % | $ 2.66 M | USA |
 |
Generation Bio Co.
GBIO
|
162 M | - | - | $ 344 M | USA |
 |
Akero Therapeutics
AKRO
|
80.2 M | - | - | $ 3.67 B | USA |
 |
AnaptysBio
ANAB
|
187 M | $ 58.47 | 4.37 % | $ 1.68 B | USA |
 |
Anika Therapeutics
ANIK
|
51.6 M | $ 21.5 | 1.56 % | $ 308 M | USA |
 |
Cyclacel Pharmaceuticals
CYCCP
|
9.17 M | - | -4.36 % | $ 27 M | USA |
 |
Gracell Biotechnologies
GRCL
|
214 M | - | - | $ 3.37 B | China |
 |
Aurinia Pharmaceuticals
AUPH
|
43.9 M | $ 15.47 | 1.91 % | $ 2.08 B | Canada |
 |
GlycoMimetics
GLYC
|
163 M | - | 9357.83 % | $ 1.01 B | USA |
 |
Aeterna Zentaris
AEZS
|
13.3 M | - | 5.93 % | $ 314 M | Canada |
 |
AVROBIO
AVRO
|
84 M | - | 1083.1 % | $ 745 M | USA |
 |
BeiGene, Ltd.
BGNE
|
390 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Bicycle Therapeutics plc
BCYC
|
320 M | $ 3.9 | 0.24 % | $ 270 M | Britain |
 |
Beam Therapeutics
BEAM
|
523 M | $ 26.75 | 0.91 % | $ 2.65 B | USA |
 |
AIkido Pharma
AIKI
|
179 M | - | 1.93 % | $ 17.4 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
210 M | - | - | $ 1.01 B | USA |
 |
BioMarin Pharmaceutical
BMRN
|
1.47 B | $ 67.36 | 0.99 % | $ 12.9 B | USA |
 |
Aptose Biosciences
APTO
|
24.7 M | - | -45.71 % | $ 1.2 M | Canada |